130 related articles for article (PubMed ID: 11082727)
1. The treatment pipeline: new therapies are on the way.
Boyle BA
AIDS Read; 1999 Nov; 9(8):519-20, 523-5, 528-9. PubMed ID: 11082727
[No Abstract] [Full Text] [Related]
2. The importance of sequencing in treatment options.
Berger DS
Posit Aware; 2001; 12(3):42-3. PubMed ID: 11686121
[No Abstract] [Full Text] [Related]
3. Short communication metabolic and mitochondrial effects of switching antiretroviral-experienced patients to enfuvirtide, tenofovir and saquinavir/ritonavir.
Miró O; Garrabou G; López S; Deig E; Vidal I; Infante AB; Cardellach F; Casademont J; Pedrol E
Antivir Ther; 2006; 11(5):625-30. PubMed ID: 16964831
[TBL] [Abstract][Full Text] [Related]
4. Darunavir offers potent new combo when used with enfuvirtide in ritonavir-boosted regimen.
Edmunds-Ogbuokiri T
HIV Clin; 2007; 19(1):1-3. PubMed ID: 17405221
[No Abstract] [Full Text] [Related]
5. Induction therapy with enfuvirtide-based highly active antiretroviral therapy in a patient with acute HIV-1 infection.
Polk C; Chan-Tack KM; Kopack AM; Amoroso A
AIDS Patient Care STDS; 2007 Feb; 21(2):75-7. PubMed ID: 17328655
[No Abstract] [Full Text] [Related]
6. T-20 being called "miraculous".
AIDS Patient Care STDS; 2002 Sep; 16(9):462. PubMed ID: 12412581
[No Abstract] [Full Text] [Related]
7. Fresh data on new anti-HIV drugs presented in Durban.
Leibovich M
Posit Living; 2000 Aug; 9(7):16-7. PubMed ID: 12492026
[No Abstract] [Full Text] [Related]
8. US FDA approves new class of HIV therapeutics.
Robertson D
Nat Biotechnol; 2003 May; 21(5):470-1. PubMed ID: 12721558
[No Abstract] [Full Text] [Related]
9. Therapies. Raising the limits.
Cohen J
Science; 2002 Jun; 296(5577):2322. PubMed ID: 12089423
[No Abstract] [Full Text] [Related]
10. [Fusion inhibitors. One year therapy with T-20--initial evaluation].
Goebel FD
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():42-3. PubMed ID: 15373046
[No Abstract] [Full Text] [Related]
11. Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide.
González de Requena D; Calcagno A; Bonora S; Ladetto L; D'Avolio A; Sciandra M; Siccardi M; Bargiacchi O; Sinicco A; Di Perri G
AIDS; 2006 Oct; 20(15):1977-9. PubMed ID: 16988521
[TBL] [Abstract][Full Text] [Related]
12. [Strategies for combating resistances in HIV therapy--an exemplifying case].
Stoehr A
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():70-1. PubMed ID: 15373056
[No Abstract] [Full Text] [Related]
13. Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies.
Negredo E; Bonjoch A; Paredes R; Puig J; Clotet B
Clin Infect Dis; 2005 Sep; 41(6):901-5. PubMed ID: 16107993
[TBL] [Abstract][Full Text] [Related]
14. Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST.
Raffi F; Battegay M; Rusconi S; Opravil M; Blick G; Steigbigel RT; Kraft M; Neubacher D; Sabo JP
AIDS; 2007 Sep; 21(14):1977-80. PubMed ID: 17721109
[TBL] [Abstract][Full Text] [Related]
15. Anti-HIV agents. Access denied--keeping HIV out with entry inhibitors.
TreatmentUpdate; 2006; 18(4):4. PubMed ID: 17205653
[No Abstract] [Full Text] [Related]
16. The clades of HIV: their origins and clinical significance.
Stebbing J; Moyle G
AIDS Rev; 2003; 5(4):205-13. PubMed ID: 15011999
[TBL] [Abstract][Full Text] [Related]
17. Drug interactions. Unexpected interaction between T-20 and some protease inhibitors.
TreatmentUpdate; 2006; 18(3):5. PubMed ID: 17209239
[No Abstract] [Full Text] [Related]
18. The safety and efficacy of granulocyte-macrophage colony-stimulating factor (Sargramostim) added to indinavir- or ritonavir-based antiretroviral therapy: a randomized double-blind, placebo-controlled trial.
Skowron G; Stein D; Drusano G; Melbourne K; Bilello J; Mikolich D; Rana K; Agosti JM; Mongillo A; Whitmore J; Gilbert MJ
J Infect Dis; 1999 Oct; 180(4):1064-71. PubMed ID: 10479132
[TBL] [Abstract][Full Text] [Related]
19. Antiviral Research--16th Annual International Conference. Satellite symposium: clinical update on antiviral drugs. 27 April-1 May 2003, Savannah, GA, USA.
Vere Hodge A
IDrugs; 2003 Jun; 6(6):515-7. PubMed ID: 12861974
[No Abstract] [Full Text] [Related]
20. [New treatments against AIDS: fusion inhibitors].
Holzgrabe U
Pharm Unserer Zeit; 2004; 33(1):6. PubMed ID: 14968706
[No Abstract] [Full Text] [Related]
[Next] [New Search]
